Taltobulin trifluoroacetate (HTI-286 trifluoroacetate) is a synthetic tripeptide cysteine analog and a potent antimicrotubule agent that overcomes P-glycoprotein-mediated drug resistance in vitro and in vivo; it inhibits purified tubulin polymerization, disrupts microtubule organization in cells, and induces mitotic arrest and apoptosis; it demonstrates potent antiproliferative activity against a broad panel of human tumor cell lines including leukemia, ovarian, non-small cell lung cancer (NSCLC), breast, colon, and melanoma with nanomolar IC50 values; it significantly inhibits the growth of various human tumor xenografts (e.g., HCT-15, DLD-1, MX-1W, KB-8-5, Lox melanoma, and KB-3-1 epidermoid carcinoma) in athymic nude mice following intravenous or oral administration.